Gemcitabine Current Events | Page 3

Gemcitabine Current Events, Gemcitabine News Articles.
Sort By: Most Viewed | Most Recent
Page 3 of 6 | 208 Results
Early clinical trial tests treatment strategy for pancreatic cancer
Pancreatic cancer carries a poor prognosis, and it often goes undetected until advanced stages. A new BJS (British Journal of Surgery) study indicates that a certain cocktail of chemotherapy drugs may be a safe and effective treatment option for patients with a metastatic form of the disease. (2020-07-08)

Harnessing anticancer drugs for the future fight against influenza
The researchers at the Institute for Molecular Medicine Finland together with their collaborators developed a new cell screening method that can be used to identify potential anti-influenza drugs. They also identified two novel anti-influenza agents. (2012-09-05)

Skin rash actually signifies better outcomes for pancreatic and lung cancer patients
The appearance of a rash in cancer patients treated with erlotinib (Tarceva) is strongly associated with longer survival, according to researchers from the drug's developer, OSI Pharmaceuticals, Inc. This is not the first time that rash has been associated with a survival advantage with EGFR inhibitors -- a class of drugs which includes erlotinib, cetuximab, panitumumab and others designed to block overproduction of the epidermal growth factor receptor -- but it is the most detailed analysis to date. (2007-07-03)

Drug for pancreatic cancer developed by college of pharmacy researchers
University of Houston researchers have developed a new medicine that can inhibit two of the major pathways of pancreatic cancer. The new synthetic compound is based on a type of sea sponge. (2018-09-11)

USC/Norris oncologists test new front-line therapy for pancreatic cancer
USC/Norris Comprehensive Cancer Center oncologists are testing the effectiveness of a new drug against pancreatic cancer in a phase II clinical trial sponsored by the NCI. (2005-01-13)

How bacteria hinder chemotherapy
Scientists find bacteria in pancreatic tumors that metabolize a common drug. (2017-09-18)

Customising chemotherapy in Lu Ca: New Ph II data reported in 2 LB studies
Measuring the expression levels of an enzyme involved in DNA synthesis can help predict the response of lung cancers to certain treatments, a Korean study has shown at the ESMO 2014 Congress in Madrid. (2014-09-27)

Modified flu virus can 'resensitize' resistant pancreatic cancer cells to chemotherapy
A common flu virus could be used to overcome patients' resistance to certain cancer drugs -- and improve how those drugs kill cancer cells, according to new research from Queen Mary University of London (QMUL). (2016-04-14)

Effectiveness of gemcitabine & daily RT for bladder preservation in muscle-invasive bladder cancer
Bladder preservation with trimodality therapy can be a safe and effective alternative to cystectomy for selected patients with muscle-invasive bladder cancer. The phase II NRG Oncology NRG-RTOG 0712 trial evaluated two regimens. One was the prior RTOG standard using 5-flourouracil and cisplatin with twice daily radiation (FCT), and the other a regimen of gemcitabine and daily radiation (GD) which had demonstrated efficacy in single institution clinical trials. (2020-10-26)

Anti-angiogenic drugs impede chemotherapy-stimulated tumor recovery
Scientists have gained new insight into a mechanism whereby chemotherapy may actually assist the rapid regrowth of tumors after treatment. (2008-09-08)

Experimental insulin-like growth factor receptor inhibitor reduced pancreatic cancer growth
Researchers at Amgen are testing a fully human monoclonal antibody that inhibits the activity of insulin-like growth factors (IGF-1 and IGF-2) and appears to reduce pancreatic cancer cells in early testing, according to a report in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research. (2009-04-14)

New generation of treatments shows promise for cancer patients
Armed with information about the function and capabilities of currently approved cancer therapies, researchers are beginning to develop more potent and successful treatments, according to research presented today at the 94th Annual Meeting of the American Association for Cancer Research (AACR). (2003-07-12)

Simple post-surgery step significantly reduces bladder cancer recurrence
It's just one step. Flushing the bladder with a common chemotherapy drug after a cancerous tumor is surgically removed reduces the chances of that cancer returning. Canadian and European clinical trials have proven this true and now a major US study has done the same. Results from the SWOG study will be presented at American Urological Association annual meeting held May 12-16 in Boston. (2017-05-15)

'Promising' antibody therapy extends survival in mice with pancreatic cancer
Scientists have found a way to target and knock out a single protein that they have discovered is widely involved in pancreatic cancer cell growth, survival and invasion. (2019-07-31)

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase III study to report findings in this setting. (2010-10-09)

A new option to ameliorate quality of life of advanced gallbladder carcinoma?
Patients with advanced gallbladder carcinoma face a dismal prognosis, as no effective palliative chemotherapy exists. A research group in China investigated the efficacy and safety of gemcitabine-oxaliplatin combined with huachansu injection (cinobufagin) treatment in patients with locally advanced or metastatic GBC, and assessed the patients' quality of life. (2008-09-19)

Simple post-surgery step reduces bladder cancer recurrence
In the latest issue of JAMA, SWOG researchers show that flushing the bladder with a common chemotherapy drug immediately after surgery significantly reduces the chances of bladder cancer returning. (2018-05-08)

Fox Chase Cancer Center physician leads new international treatment study for ovarian cancer
An international clinical study to evaluate new treatments for women with ovarian cancer is now open in the U.S. This randomized study will compare the overall effectiveness of the standard treatment (a combination of paclitaxel and carboplatin) for ovarian cancer with recently developed chemotherapy combinations incorporating newer drugs. (2001-03-04)

Predicting the risk of severe side effects of cancer treatment
The risk of serious adverse effects on the blood status and bone marrow of patients during chemotherapy can be predicted by a model developed at Linköping University, Sweden. This research may make it possible to use genetic analysis to identify patients with a high probability of side effects. The study has been published in npj Systems Biology and Applications. (2020-11-12)

Death, division or cancer? Newly discovered checkpoint process holds the line in cell division
Researchers from Fox Chase Cancer Center and Technion-Israel Institute of Technology in Haifa, Israel, have discovered a novel biochemical activity involved in controlling cell division, which they've called the mitotic checkpoint factor 2. While the proteins involved in MCF2 remain to be determined, their findings offer insight into a fundamental question of biology, which may also help to increase the efficiency of cancer drugs like gemcitabine or paclitaxel. (2008-07-01)

Pre-surgery chemotherapy is possible for early stage pancreatic cancer patients
A first-of-its-kind randomized clinical trial found that patients with pancreatic cancer didn't live any longer than expected after receiving pre-operative chemotherapy from either of the two standard regimens, according to trial results published in JAMA Oncology. (2021-01-21)

MM-398 added to standard treatment shows survival benefit in mets pancreatic cancer
Adding the novel MM-398 to standard treatment for metastatic pancreatic cancer patients who have already received gemcitabine improves survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. (2014-06-25)

TGen and Scottsdale Healthcare cancer expert Dr. Daniel D. Von Hoff is honored by ASCO
In association with its 50th anniversary, the American Society of Clinical Oncology (ASCO) has named Dr. Daniel D. Von Hoff one of ASCO's 50 Oncology Luminaries, celebrating 50 doctors who over the past half-century have significantly advanced cancer care. (2014-03-07)

Western University hopes to use artificial intelligence to improve breast cancer patient outcomes
Western University researchers are working on a way to use artificial intelligence to predict a patient's response to two common chemotherapy medications used to treat breast cancer -- paclitaxel and gemcitabine. Peter Rogan, Ph.D., and a team of researchers, including Stephanie Dorman, Ph.D., and Katherina Baranova, B.M.Sc., at Western's Schulich School of Medicine & Dentistry, are hoping to one day remove the guesswork from breast cancer treatment with this technique. (2015-09-18)

Significant survival gains from neoadjuvant chemotherapy for high-risk soft tissue sarcoma
Neoadjuvant chemotherapy with an anthracycline plus ifosfamide was associated with significant survival gains in patients with soft tissue sarcoma of the trunk or extremities who are at high-risk of recurrence, in an interim analysis that led to the early discontinuation of a trial presented today at the ESMO 2016 Congress in Copenhagen. (2016-10-10)

'Time machine' offers new pancreatic cancer drug testing approach
Drug resistance is a major reason why pancreatic cancer has a five-year survival rate of only about 10%. If scientists tested potential drugs on multiple tumor cell subtypes rather than on just one subtype, they may be able to catch resistance better, suggests a ''time machine'' developed by Purdue University engineers. (2020-10-29)

Moffitt researchers compare chemotherapy regimens for best outcomes in invasive bladder cancer
Patients with muscle-invasive bladder cancer have been shown to benefit from chemotherapy prior to surgical removal of the bladder. But which type of chemotherapy leads to the best outcomes in terms of complete response rates or cancer control? Moffitt Cancer Center researchers examined data from more than 800 surgical patients with advanced bladder cancer. The results, published online by JAMA Oncology, show higher likelihoods of complete response or down-staging associated with a chemotherapeutic combination called ddMVAC. (2018-08-31)

Jefferson researchers receive W.W. Smith Charitable Trust
Thomas Jefferson University researchers have been awarded a W.W. Smith Charitable Trust medical research grant. This one-year grant awards $100,000 to help support their innovative cancer research, and one of the questions they will address is why African-Americans respond poorly to common chemotherapeutic agents used to treat pancreatic cancer. (2010-11-08)

Best care for the oldest lung cancer patients
Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce. Now Italian oncologists are conducting a number of trials targeting elderly patients with non-small cell lung cancer, and offer a review of the latest findings -- and their recommendations -- in the current issue of Therapeutic Advances in Medical Oncology, published by SAGE. (2010-04-29)

Erlotinib improves progression-free survival in early mutated non-small cell lung cancer
Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer (NSCLC), shows a randomised study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich. (2018-10-21)

AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative breast cancer cells express estrogen receptors, and that increases the sensitivity of these cells to chemotherapy. (2013-04-07)

FDA approves drug tested by Scottsdale Healthcare and TGen
Abraxane, the brand name for nab-paclitaxel, was approved for use in combination with gemcitabine, the previous standard drug therapy, following a large scale international clinical trial headed by Dr. Daniel D. Von Hoff, TGen Physician-in-Chief and Chief Scientific Officer at Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials, a partnership of Scottsdale Healthcare and TGen. (2013-09-06)

RTOG initiates a phase I trial testing the therapy ganitumab for locally advanced pancreatic cancer
Conducted by the Radiation Therapy Oncology Group, the results of the RTOG 1102 are expected to provide important dosing and safety information needed prior to advancing ganitumab evaluation to a phase II randomized trial. (2011-12-14)

Antibody-drug conjugate may provide new treatment option for pancreatic cancer patients
Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23. (2013-10-21)

DSI professor conducts research to combat pancreatic cancer
Tal Danino, a professor at the Data Science Institute, is conducting research that could help scientists combat the most lethal of cancers: pancreatic cancer. In a recent study, working with a team of researchers, Danino demonstrated that bacteria in pancreatic tumors degrade a chemotherapy drug -- Gemcitabine -- most commonly used to treat patients who have pancreatic cancer. (2017-10-05)

TGen/Virginia G. Piper Cancer Center publish results of new drug for pancreatic cancer patients
Patients at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare were the first in the nation to participate in a clinical trial to determine the safety, tolerability and effectiveness for usage of a new drug combination consisting of a standard drug called gemcitabine and a drug called nab-paclitaxel for patients with advanced pancreatic cancer. The study results are published in the prestigious Journal of Clinical Oncology. (2011-10-04)

Drug combination extends survival in mesothelioma
Patients with pleural mesothelioma live longer and have less pain and shortness of breath when treated with a combination of cisplatin and pemetrexed. This drug combination caused the cancer to shrink in 41 percent of patients. This is the first therapy to show a benefit for this type of cancer. (2003-07-14)

Mayo Clinic discovers 'new pathway' against pancreatic cancer
Pancreatic cancer kills 30,000 Americans every year. Not only is there no cure, but there are no effective treatments. That may change if a new finding by Mayo Clinic researchers continues to show promise. (2005-03-15)

Despite failures, chemo still promising against dangerous childhood brain cancer, DIPG
University of Colorado Cancer Center study shows, '... medicine does reach DIPG tissue in good quantities that have the potential to be effective against the tumor,' says lead researcher. (2020-03-25)

Liverpool to trial new pancreatic cancer therapy
Patients in Liverpool are to trial a new therapy for pancreatic cancer -- a disease which sees most sufferers die within a year of diagnosis. (2007-03-15)

Page 3 of 6 | 208 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to